SSTR2

Monopar Receives Clearance to Proceed with First-in-Human Phase 1 Trial of Novel Radiopharmaceutical MNPR-101-Zr in Advanced Cancers

Retrieved on: 
Tuesday, February 20, 2024
Actinium-225, MD, Neoplasm, Cancer, PSMA, Safety, Therapy, Receptor (biochemistry), Patient, SSTR2, Clinical trial, PET, Human, Pharmaceutical industry

The MNPR-101-Zr Phase 1 dosimetry clinical trial will enroll patients with advanced cancers and will utilize positron emission tomography (PET) imaging to assess tumor uptake, normal organ biodistribution, and safety.

Key Points: 
  • The MNPR-101-Zr Phase 1 dosimetry clinical trial will enroll patients with advanced cancers and will utilize positron emission tomography (PET) imaging to assess tumor uptake, normal organ biodistribution, and safety.
  • PET imaging studies in preclinical xenograft models of triple-negative breast, colorectal, and pancreatic cancers displayed high and selective uptake of MNPR-101-Zr in these uPAR-expressing tumors.
  • “This is a significant milestone for Monopar,” said Chandler Robinson, MD, Monopar’s Chief Executive Officer.
  • “Following more than 18 months of extensive preclinical development, we believe we are well-positioned in this space.

Bristol Myers Squibb Completes Acquisition of RayzeBio, Adding Differentiated Actinium-Based Radiopharmaceutical Platform

Retrieved on: 
Monday, February 26, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Acquisition, BMY, Covington & Burling, Growth, RPT, Bristol Myers Squibb, Cooley LLP, Patient, SSTR2, BofA Securities, Tax, Eastern Time Zone, LLP, IND, Centerview Partners, Pharmaceutical industry

Bristol Myers Squibb (NYSE: BMY) announced today that it has successfully completed its acquisition of RayzeBio, Inc. (NASDAQ: RYZB).

Key Points: 
  • Bristol Myers Squibb (NYSE: BMY) announced today that it has successfully completed its acquisition of RayzeBio, Inc. (NASDAQ: RYZB).
  • With the completion of the acquisition, RayzeBio shares have ceased trading on the NASDAQ Global Market and RayzeBio is now a wholly owned subsidiary of Bristol Myers Squibb.
  • “We are excited to complete this transaction, which adds radiopharmaceutical therapeutics (RPTs), one of the fastest-growing new modalities for treating patients with solid tumors,” said Chris Boerner, Ph.D., Chief Executive Officer, Bristol Myers Squibb.
  • BofA Securities, Inc., is serving as financial advisor to Bristol Myers Squibb, and Covington & Burling LLP is serving as legal counsel.

Perspective Commences Recruitment for Second Dose Escalation Cohorts in Clinical Studies of Two Lead Programs: [(212)Pb]VMT-α-NET and [(212)Pb]VMT01

Retrieved on: 
Wednesday, January 17, 2024
Cohort, SSTR2, Neoplasm, Lutetium (177Lu) oxodotreotide, Patient, Therapy, Safety, CATX, TAT, Pharmaceutical industry

In addition, the first patient in cohort 2 of the [212Pb]VMT01 study was already dosed.

Key Points: 
  • In addition, the first patient in cohort 2 of the [212Pb]VMT01 study was already dosed.
  • [212Pb]VMT01 is a TAT in development for second-line or later treatment of patients with progressive MC1R-positive metastatic melanoma.
  • “Preliminary safety data from these Phase 1 studies of [212Pb]VMT-α-NET and [212Pb]VMT01 demonstrate good tolerability and support further dose escalation.
  • The [212Pb]VMT-α-NET data are consistent with the data collected at similar doses from the clinician-initiated ongoing study in India.

Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio

Retrieved on: 
Tuesday, December 26, 2023
Actinium, Hart–Scott–Rodino Antitrust Improvements Act, BMY, SSTR2, Bristol Myers Squibb, Hepatocellular carcinoma, Drug development, LLP, Acquisition, Centerview Partners, SAN, Carcinoma, BofA Securities, HCC, Covington & Burling, GMP, Cancer, CA9, Growth, Patient, Therapy, GPC3, Radioactive decay, Cooley LLP, Radiation, Pharmaceutical industry

PRINCETON, N.J. and SAN DIEGO, Dec. 26, 2023 (GLOBE NEWSWIRE) -- Bristol Myers Squibb (NYSE: BMY) and RayzeBio, Inc. (NASDAQ: RYZB) today announced a definitive merger agreement under which Bristol Myers Squibb will acquire RayzeBio for $62.50 per share in cash, for a total equity value of approximately $4.1 billion, or $3.6 billion net of estimated cash acquired. The transaction was unanimously approved by both the Bristol Myers Squibb and RayzeBio Boards of Directors.

Key Points: 
  • The transaction was unanimously approved by both the Bristol Myers Squibb and RayzeBio Boards of Directors.
  • “Radiopharmaceutical therapeutics are already transforming cancer care, and RayzeBio is at the forefront of pioneering the application of this novel modality.
  • Bristol Myers Squibb expects to finance the acquisition with primarily new debt issuance.
  • BofA Securities, Inc., is serving as financial advisor to Bristol Myers Squibb, and Covington & Burling LLP is serving as legal counsel.

Perspective Therapeutics Announces First Patient Dosed in a Phase 1 Study of [(212)Pb]VMT-α-NET to Treat Refractory or Relapsed Neuroendocrine Tumors

Retrieved on: 
Thursday, December 7, 2023
University, SSTR2, Neoplasm, Perspective, TAT, NETS, Therapy, Standard of care, PRRT, Patient, CATX, Safety, DOTATATE, Glomus tumor, Pharmaceutical industry

The patients being enrolled in the study have either progressed or relapsed after previous therapies, including currently approved peptide receptor radionuclide therapies (“PRRT”).

Key Points: 
  • The patients being enrolled in the study have either progressed or relapsed after previous therapies, including currently approved peptide receptor radionuclide therapies (“PRRT”).
  • The trial is a single-center, open-label study of [212Pb]VMT-α-NET that is designed to explore safety and efficacy when pre-treatment dose planning is aided by imaging with [203Pb]VMT-α-NET using quantitative SPECT/CT imaging.
  • “We are delighted that this innovative investigator-initiated study has commenced in refractory and relapsed neuroendocrine tumor patients,” said Thijs Spoor, Chief Executive Officer at Perspective Therapeutics.
  • We are excited by this collaboration, and we look forward to the Iowa team presenting preliminary findings in 2024.”

Perspective Therapeutics Announces First Ever Human SPECT Imaging of Pb-212 with VMT-α-NET by Clinical Collaborators in Germany

Retrieved on: 
Tuesday, November 28, 2023
Molecular imaging, SSTR2, Food, Perspective, NET, Physician, Nuclear medicine, PET/CT, SPECT/CT, Patient safety, NETS, Half-life, Therapy, Liver disease, Neoplasm, Isotope, Noise, Siemens Healthineers, Patient, CATX, Diagnosis, SPECT, European Journal, Institute of technology, DOTATATE, Glomus tumor, Medical imaging

SEATTLE, Nov. 28, 2023 (GLOBE NEWSWIRE) --  Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), today announced the publication of the first human SPECT images utilizing the alpha-emitting isotope of 212Pb, which was labeled to the Company’s proprietary theranostic VMT-α-NET product. The imaging was conducted as part of a series of four neuroendocrine tumor (NET) patients who were administered VMT-α-NET at a clinical study site in Germany. The Company is developing VMT-α-NET for the treatment and diagnosis of somatostatin receptor subtype 2 (SSTR2)-expressing neuroendocrine tumors.

Key Points: 
  • The imaging was conducted as part of a series of four neuroendocrine tumor (NET) patients who were administered VMT-α-NET at a clinical study site in Germany.
  • VMT-α-NET is being administered under the supervision of Prof. Dr. Jörg Kotzerke, Director of the Department of Nuclear Medicine at the Technical University of Dresden in Germany.
  • The SPECT/CT images showed high accumulation of [212Pb]VMT-α-NET in liver metastases and were consistent with the previously acquired [68Ga]DOTATATE PET/CT.
  • Perspective Therapeutics supplies a generator, drug precursors and isotopes for the local production of its proprietary radiotherapeutic, VMT-α-NET.

Perspective Therapeutics Announces Publication of Four Preclinical Studies in Peer-Reviewed Journals

Retrieved on: 
Monday, November 27, 2023
University of Alabama, Molecular imaging, VMT, Hospital, SSTR2, Neoplasm, University college, Survival, University of Iowa, NGAL, Veterinary medicine, Biology, Lipocalin-2, RPDC, Nuclear Medicine and Biology, Becquerel, Nuclear medicine, University, Quality control, Medicine, Doctor of Philosophy, Therapy, TU Dresden, Korea Military Academy, Knowledge, Biomarker, Toxicity, CATX, Radiopharmaceutical, PB, European Journal, Journal, Institute of technology, Glomus tumor, Medical imaging

SEATTLE, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. (NYSE AMERICAN: CATX), today announced the publication of four preclinical studies in support of the Company’s discovery pipeline. The studies were published in the European Journal of Nuclear Medicine and Molecular Imaging, Journal of Nuclear Medicine, and Pharmaceuticals.

Key Points: 
  • SEATTLE, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. (NYSE AMERICAN: CATX), today announced the publication of four preclinical studies in support of the Company’s discovery pipeline.
  • The studies were published in the European Journal of Nuclear Medicine and Molecular Imaging, Journal of Nuclear Medicine, and Pharmaceuticals.
  • “The results from these preclinical studies are compelling and continue to support our ongoing clinical efforts to advance our novel lead-based targeted alpha-particle therapies.
  • Author Affiliations: University of Alabama at Birmingham, Alabama, USA; Perspective Therapeutics, Coralville, Iowa, USA; The University of Iowa, Iowa City, Iowa, USA.

 Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio

Retrieved on: 
Tuesday, December 26, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Actinium, Hart–Scott–Rodino Antitrust Improvements Act, BMY, SSTR2, Bristol Myers Squibb, Hepatocellular carcinoma, Multimedia, Drug development, LLP, Acquisition, Centerview Partners, Carcinoma, BofA Securities, HCC, Covington & Burling, GMP, Cancer, CA9, Growth, Patient, Therapy, GPC3, Radioactive decay, Cooley LLP, Radiation, Pharmaceutical industry

Bristol Myers Squibb (NYSE: BMY) and RayzeBio, Inc. (NASDAQ: RYZB) today announced a definitive merger agreement under which Bristol Myers Squibb will acquire RayzeBio for $62.50 per share in cash, for a total equity value of approximately $4.1 billion, or $3.6 billion net of estimated cash acquired.

Key Points: 
  • Bristol Myers Squibb (NYSE: BMY) and RayzeBio, Inc. (NASDAQ: RYZB) today announced a definitive merger agreement under which Bristol Myers Squibb will acquire RayzeBio for $62.50 per share in cash, for a total equity value of approximately $4.1 billion, or $3.6 billion net of estimated cash acquired.
  • The transaction was unanimously approved by both the Bristol Myers Squibb and RayzeBio Boards of Directors.
  • Bristol Myers Squibb expects to finance the acquisition with primarily new debt issuance.
  • BofA Securities, Inc., is serving as financial advisor to Bristol Myers Squibb, and Covington & Burling LLP is serving as legal counsel.

Perspective Therapeutics Completes Initial Dose Escalation Cohort for Second Novel Targeted Alpha Therapy

Retrieved on: 
Thursday, November 16, 2023
SSTR2, NYSE, Therapy, NETS, Clinical trial, Patient, University, Clinical professor, MD, CATX, Mayo Clinic, Glomus tumor, Pharmaceutical industry

This milestone follows the recent completion of the first dose escalation cohort for Perspective’s melanoma therapeutic [212Pb]VMT01.

Key Points: 
  • This milestone follows the recent completion of the first dose escalation cohort for Perspective’s melanoma therapeutic [212Pb]VMT01.
  • “We are pleased with the progress of our Company-sponsored clinical evaluation of [212Pb]VMT-α-NET in patients with difficult-to-treat SSTR2-expressing NETs.
  • The rapid recruitment into this study reflects the demand for potent alpha-particle therapies that exists in this patient population,” commented Markus Puhlmann, Chief Medical Officer of Perspective Therapeutics.
  • Overall, the Company remains on track to launch an additional 14 clinical trial sites throughout the U.S. including the Mayo Clinic, the University of Iowa and more.

RayzeBio Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, November 13, 2023
SSTR2, SAN, GMP, Initial public offering, Investment, Liver cancer, ESMO, Administration, Patient, Radiopharmaceutical, Research, GPC3, ORR, IPO, Cancer, R, Research and development, Growth, HCC, PR, Pharmaceutical industry, IND

SAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- RayzeBio, Inc. (Nasdaq: RYZB), a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, today reported financial results for the third quarter ended September 30, 2023 and provided an update on key corporate initiatives.

Key Points: 
  • SAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- RayzeBio, Inc. (Nasdaq: RYZB), a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, today reported financial results for the third quarter ended September 30, 2023 and provided an update on key corporate initiatives.
  • As part of the IPO and subsequently at ESMO in October 2023, RayzeBio reported the interim results of the Phase 1b portion of the ACTION-1 clinical trial, where RayzeBio enrolled a total of 17 patients.
  • Research and Development (R&D) Expenses: R&D expenses for the third quarter of 2023 were $18.2 million, compared to $18.8 million for the third quarter of 2022.
  • Net Loss: Net loss for the third quarter of 2023 was $18.2 million, compared to the net loss for the third quarter of 2022 which was $20.4 million.